Pliant Therapeutics (NASDAQ:PLRX) Price Target Cut to $1.50 by Analysts at Citigroup
Pliant Therapeutics (NASDAQ:PLRX – Free Report) had its price objective lowered by Citigroup from $4.00 to $1.50 in a report ...
The Pharma Letter4h
Pliant halts lung fibrosis trial amid safety concerns
Pliant Therapeutics has scrapped its Phase IIb Beacon-IPF trial for bexotegrast in idiopathic pulmonary fibrosis (IPF), after ...
Hosted on MSN23h
Leerink Partners Downgrades Pliant Therapeutics (PLRX)
Fintel reports that on March 3, 2025, Leerink Partners downgraded their outlook for Pliant Therapeutics (NasdaqGS:PLRX) from ...
Pliant Therapeutics Drops IPF Drug Trial After Review, Analyst Flags Uncertain Future
Pliant Therapeutics ends its Phase 2b IPF trial for bexotegrast, prompting a Needham downgrade to Hold due to limited ...
Pliant Therapeutics (NASDAQ:PLRX) Rating Lowered to “Hold” at Stifel Nicolaus
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) was downgraded by equities research analysts at Stifel Nicolaus from a “buy” rating to a “hold” rating in a research note issued on Monday, ...
Pliant Therapeutics price target lowered to $1.50 from $4 at Citi
Citi lowered the firm’s price target on Pliant Therapeutics (PLRX) to $1.50 from $4 and keeps a Neutral rating on the shares. The company ...
Pliant Therapeutics Stock Sinks, Discontinues Mid-Stage Study For Lung Disorder
Pliant Therapeutics discontinued its BEACON-IPF trial for bexotegrast due to safety concerns but observed early efficacy. The ...
Pliant Therapeutucs Shares Halted After Bexotegrast Phase 2b Trial Discontinued
Pliant Therapeutics shares were halted in early morning trading after falling 25% to $2.57, after the company said it is discontinuing a phase 2b trial for bexotegrast in patients with idiopathic ...
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results
Discontinuation of BEACON-IPF following DSMB and outside expert panel recommendationSOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE ...